We selected KRAS, EGFR, BRAF, and MET mutations for inclusion in the multivariable model because they are among the most commonly altered driver mutations in LUAD and are known to significantly influence tumor behavior, prognosis, and response to targeted therapies. The gene discussed is BRAF; the disease is neoplasm.